Brad Hively Biography and Net Worth

Director of Oncology Institute

Brad Hively served as Chief Executive Officer of TOI from 2019-2023 and has since transitioned to Vice Chairman of the Board. Prior to joining TOI, Mr. Hively served as a principal for RLH Equity Partners from 2016 to 2019 and continues to serve as a Strategic Advisor for RLH. Mr. Hively served as President of Health Essentials, which provided high-touch, value-based care to post-acute and palliative care patients from 2014 to 2015. Prior to Health Essentials, from 2009 to 2014, Mr. Hively served as Senior Vice President of Operations at Heritage Provider Network, one of the largest physician groups in the U.S., and one of the pioneers of value-based care. Mr. Hively has also held roles with several leading private equity firms, including TA Associates, General Atlantic, and ROCA Partners. Mr. Hively holds a B.A. in Business Economics from University of California, Los Angeles and an M.B.A. from the Stanford University Graduate School of Business.

What is Brad Hively's net worth?: The estimated net worth of Brad Hively is at least $2.45 million as of August 21st, 2026. Mr. Hively owns 411,976 shares of Oncology Institute stock worth more than $2,451,257 as of September 4th. This net worth evaluation does not reflect any other assets that Mr. Hively may own. Learn More about Brad Hively's net worth.
How do I contact Brad Hively?: The corporate mailing address for Mr. Hively and other Oncology Institute executives is 18000 STUDEBAKER RD, SUITE 800, CERRITOS, CA, 90703. Oncology Institute can also be reached via phone at (562) 735-3226 and via email at [email protected]. Learn More on Brad Hively's contact information.
Has Brad Hively been buying or selling shares of Oncology Institute?: Within the last three months, Brad Hively has sold $1,945,533.03 in shares of Oncology Institute stock. Most recently, Brad Hively sold 298,853 shares of the business's stock in a transaction on Friday, August 21st. The shares were sold at an average price of $6.51, for a transaction totalling $1,945,533.03. Following the completion of the sale, the director now directly owns 411,976 shares of the company's stock, valued at $2,681,963.76. Learn More on Brad Hively's trading history.
Who are Oncology Institute's active insiders?: Oncology Institute's insider roster includes Robert Carter (CFO), Jorey Chernett (Major Shareholder), Brad Hively (Director), Mohit Kaushal (Director), Mark Pacala (Director), Yale Podnos (Director), and Daniel Virnich (CEO). Learn More on Oncology Institute's active insiders.
Are insiders buying or selling shares of Oncology Institute?: In the last twelve months, Oncology Institute insiders bought shares 14 times. They purchased a total of 712,485 shares worth more than $2,447,345.65. In the last twelve months, insiders at the sold shares 9 times. They sold a total of 7,181,603 shares worth more than $23,360,860.64. The most recent insider tranaction occured on August, 21st when Director Brad Hively sold 298,853 shares worth more than $1,945,533.03. Insiders at Oncology Institute own 4.4% of the company. Learn More about insider trades at Oncology Institute.
Information on this page was last updated on 8/21/2026.

Brad Hively Insider Trading History at Oncology Institute

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/15/2025	Sell	13,333	$3.77	$50,265.41	683,721
6/3/2025	Sell	1,976,137	$2.87	$5,671,513.19	603,501
12/2/2024	Buy	50,000	$0.15	$7,500.00	666,753
11/26/2024	Buy	250,000	$0.17	$42,500.00	616,753
11/17/2023	Sell	25,000	$2.24	$56,000.00	697,065
11/13/2023	Sell	47,000	$2.52	$118,440.00	724,182

Brad Hively Buying and Selling Activity at Oncology Institute

Oncology Institute Company Overview

The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants for cancer patients. The company was founded in 2007 and is based in Cerritos, California.

Today's Range

Now: $5.95

$5.87

$5.97

50 Day Range

MA: N/A

2 Week Range

Now: $5.95

$2.32

$7.05

Volume

116,922 shs

Average Volume

1,839,387 shs

Market Capitalization

$588.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.41